Gamida Cell Ltd. (GMDA) Misses Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts GMDA Hot Sheet
Join SI Premium – FREE
Gamida Cell Ltd. (NASDAQ: GMDA) reported Q2 EPS of ($0.31), $0.02 worse than the analyst estimate of ($0.29).
Finished second quarter of 2022 with $55.1 million in cash; sufficient funding for the company’s operations into mid-2023, excluding the cost of commercializing omidubicel.
For earnings history and earnings-related data on Gamida Cell Ltd. (GMDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Southwest Gas (SWX) Tops Q3 EPS by 2c; Offers Guidance
- SmartRent (SMRT) Reports In-Line Q3 EPS
- Leidos Holdings (LDOS) PT Lowered to $138 at Stifel
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
